Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ART (Advanced Research Technologies) enters SoftScan into North American pivotal trials

This article was originally published in Clinica

Executive Summary

Canadian imaging firm Advanced Research Technologies (ART) has moved its breast cancer detection technology, SoftScan, into North American pivotal trials. The company intends to use results of the study, taking place at the McGill University Health Center in Montreal, Canada, in support of marketing applications to the US FDA, under a premarket approval (PMA) application, and Health Canada. The study, which is expected to run through into 2006, will examine the clinical safety and effectiveness of SoftScan in 600-950 women aged 25-60. SoftScan is a noninvasive, nonionising optical imaging technology used in adjunct to mammography to help doctors diagnose and manage breast cancer. It uses near infrared light to help differentiate between benign and malignant structures, thus preventing patients from having to undergo unnecessary and unpleasant biopsies, the Montreal firm said.

You may also be interested in...

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts